Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Development and validation of a novel 3D human in vitro model of nonalcoholic steatohepatitis to be used for novel therapeutic screening and research on disease mechanism.

Award Number: R44DK115242
ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/18/2017
PERIOD OF PERFORMANCE END DATE: 12/31/2021

Group Awards By:

View Award Description

Development and validation of a novel 3D human in vitro model of nonalcoholic steatohepatitis to be used for novel therapeutic screening and research on disease mechanism. - ABSTRACT Nonalcoholic fatty liver disease (NAFLD) is a chronic condition that originates as lipid accumulation within hepatocytes (steatosis) and progresses into nonalcoholic steatohepatitis (NASH), characterized by lipid accumulation, inflammation, oxidative stress, and fibrosis. An estimated 100 million adults across the U.S. are thought to have NAFLD, with up to 20 million more estimated to have NASH. Left unchecked, the disease can advance to cirrhosis and hepatocellular carcinoma. Currently, NASH contributes to one third of hepatocellular carcinomas in the US and is the second leading cause of liver transplants in the US. NASH is often referred to as a “silent” disease as most patients are asymptomatic until problems arise from cirrhosis and liver failure and diagnosis only possible via invasive liver biopsies. Despite well-defined morphological features and decades of intense research worldwide, the mechanisms of NAFLD progression as well as therapeutic approaches and non-invasive diagnostics are still resoundingly absent. Recently, Organovo developed ExVive™ Human Liver Tissue, an in vitro 3D bioprinted liver model comprising primary human hepatocytes, hepatic stellates and endothelial cells that better mimics native human liver biology over extended time in culture. The technological advancement of 3D bioprinting enables controlled, reproducible fabrication of 3D liver tissues ex vivo from human cells, yielding a durable liver model with complex composition and architecture that retains metabolic competence and liver-specific functions for at least 4 weeks in culture. The current Fast Track SBIR application seeks to utilize ExVive™ Human Liver Tissue to model the onset and progression of human NAFLD via nutrient overload in the first Phase, followed by induction of inflammation, oxidative stress and fibrosis to mimic human NASH in the second Phase. Importantly, in order to drive adoption, the steatosis and NASH models will be validated via comparisons of genomic data with clinically confirmed NAFLD patient data in collaboration with key opinion leader Dr. David Brenner, and verification of altered drug metabolism and disposition via CYP1A2 and 2C9 activities. Lastly, prevention of NAFLD progression and regression of NASH will be assessed via therapeutic modulation of disease phenotypes. Together, these in vitro models have the potential to significantly impact liver disease research by enabling the discovery of novel therapeutics, biomarkers to non-invasively delineate NASH from steatosis, and allow the safety assessment of drugs in a disease relevant background.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2023 ( Subtotal = -$2 )
2023	2019	ORGANOVO, INC.	6275 NANCY RIDGE DR STE 110	SAN DIEGO	CA	92121	SAN DIEGO	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	3	2/2/2023	NON-COMPETING CONTINUATION	-$2
														Subtotal = -$2

Issue Date FY: 2021 ( Subtotal = $0 )
2021	2019	ORGANOVO, INC.	6275 NANCY RIDGE DR STE 110	SAN DIEGO	CA	92121	SAN DIEGO	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	3	1/6/2021	NON-COMPETING CONTINUATION	$0
2021	2019	ORGANOVO, INC.	6275 NANCY RIDGE DR STE 110	SAN DIEGO	CA	92121	SAN DIEGO	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	001	3	7/7/2021	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2019 ( Subtotal = $653,558 )
2019	2019	ORGANOVO, INC.	6275 NANCY RIDGE DR STE 110	SAN DIEGO	CA	92121	SAN DIEGO	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	3	12/6/2018	NON-COMPETING CONTINUATION	$653,558
														Subtotal = $653,558

Issue Date FY: 2018 ( Subtotal = $782,018 )
2018	2018	ORGANOVO, INC.	6275 NANCY RIDGE DR STE 110	SAN DIEGO	CA	92121	SAN DIEGO	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	2	2/28/2018	EXTENSION WITH OR WITHOUT FUNDS	$782,018
														Subtotal = $782,018

Issue Date FY: 2017 ( Subtotal = $221,725 )
2017	2017	ORGANOVO, INC.	6275 NANCY RIDGE DR STE 110	SAN DIEGO	CA	92121	SAN DIEGO	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	001	1	8/24/2017	NEW	$0
2017	2017	ORGANOVO, INC.	6275 NANCY RIDGE DR STE 110	SAN DIEGO	CA	92121	SAN DIEGO	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	7/14/2017	NEW	$221,725
														Subtotal = $221,725

Grand Total All Awards = $1,657,299

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Development and validation of a novel 3D human in vitro model of nonalcoholic steatohepatitis to be used for novel therapeutic screening and research on disease mechanism.

Award Number: R44DK115242

ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/18/2017

PERIOD OF PERFORMANCE END DATE: 12/31/2021

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer